-
EP3208337
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3208337
| EP3208337 - COMPOSITIONS FOR COMBINED INHIBITION OF MUTANT EGFR AND IL-6 EXPRESSION [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 17.08.2018 Database last updated on 11.05.2024 | |
| Former | Request for examination was made Status updated on 21.07.2017 | Most recent event Tooltip | 17.08.2018 | Application deemed to be withdrawn | published on 19.09.2018 [2018/38] | Applicant(s) | For all designated states Alnylam Pharmaceuticals, Inc. 300 Third Street Cambridge, MA 02142 / US | For all designated states Alnylam Europe AG. 300 Third Street Cambridge, MA 02142 / US | For all designated states The Regents of the University of California 1111 Franklin Street Oakland, CA 94607-5200 / US | [2017/34] | Inventor(s) | 01 /
SAH, Dinah c/o Alnylam Pharmaceuticals, Inc. 300 Third Street Cambridge, MA 02142 / US | 02 /
TAN, Pamela c/o Alnylam Pharmaceuticals, Inc. 300 Third Street Cambridge, MA 02142 / US | 03 /
PEREZ, Maria Del Mar Inda 9500 Gilman Drive Cellular and Molecular Medicine - East 3041 La Jolla, CA 92093-0660 / US | 04 /
FURNARI, Frank 9500 Gilman Drive Cellular and Molecular Medicine - East 3041 La Jolla, CA 92093-0660 / US | 05 /
CAVENEE, Webster 9500 Gilman Drive Cellular and Molecular Medicine - East 3041 La Jolla, CA 92093-0660 / US | 06 /
BONAVIA, Rudy 9500 Gilman Drive Cellular and Molecular Medicine - East 3041 La Jolla, CA 92093-0660 / US | [2017/34] | Representative(s) | Vossius & Partner Patentanwälte Rechtsanwälte mbB Siebertstrasse 3 81675 München / DE | [2017/34] | Application number, filing date | 16205971.1 | 02.09.2009 | [2017/34] | Priority number, date | US20080093620P | 02.09.2008 Original published format: US 93620 P | US20080095487P | 09.09.2008 Original published format: US 95487 P | US20090147668P | 27.01.2009 Original published format: US 147668 P | US20090147680P | 27.01.2009 Original published format: US 147680 P | US20090166488P | 03.04.2009 Original published format: US 166488 P | [2017/34] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP3208337 | Date: | 23.08.2017 | Language: | EN | [2017/34] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 19.06.2017 | Classification | IPC: | C12N15/113, A61P35/00, A61K31/713 | [2017/34] | CPC: |
C12N15/1138 (EP,US);
A61K31/713 (EP,US);
A61P35/00 (EP,US);
C12N15/1136 (US);
C12N2310/14 (EP,US);
C12N2310/315 (US);
C12N2310/321 (EP,US);
C12N2310/3515 (EP,US);
C12N2320/30 (US);
C12N2320/31 (EP,US)
(-)
| C-Set: |
C12N2310/321, C12N2310/3521 (EP,US)
| Designated contracting states | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR [2017/34] | Extension states | AL | 21.01.2017 | BA | 21.01.2017 | RS | 21.01.2017 | Title | German: | ZUSAMMENSETZUNGEN ZUR KOMBINATIONSHEMMUNG DER EXPRESSION EINES MUTANTEN EGFR UND IL-6 | [2017/34] | English: | COMPOSITIONS FOR COMBINED INHIBITION OF MUTANT EGFR AND IL-6 EXPRESSION | [2017/34] | French: | COMPOSITIONS D'INHIBITION COMBINÉ D'EXPRESSION DU MUTANT EGFR ET IL-6 | [2017/34] | Examination procedure | 21.12.2016 | Date on which the examining division has become responsible | 21.01.2017 | Examination requested [2017/34] | 24.02.2018 | Application deemed to be withdrawn, date of legal effect [2018/38] | 11.04.2018 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2018/38] | Parent application(s) Tooltip | EP09792177.9 / EP2331690 | EP13179293.9 / EP2690175 | Fees paid | Renewal fee | 20.04.2017 | Renewal fee patent year 03 | 20.04.2017 | Renewal fee patent year 04 | 20.04.2017 | Renewal fee patent year 05 | 20.04.2017 | Renewal fee patent year 06 | 20.04.2017 | Renewal fee patent year 07 | 27.01.2017 | Renewal fee patent year 08 | 27.09.2017 | Renewal fee patent year 09 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [A]WO03070912 (RIBOZYME PHARM INC [US], et al) [A] 1-8 * pages 44,57,60; figure 20; example 9; tables 3,5 *; | [YD]WO2007064846 (INTRADIGM CORP [US], et al) [YD] 2 * claims 1-3, 27; table 6 *; | [YP]WO2008109350 (MDRNA INC [US], et al) [YP] 2 * figure 1; claims 1-24; table 1; sequences 158, 1160-1381 *; | [IY] - FAN QI-WEN ET AL, "RNA interference against a glioma-derived allele of EGFR induces blockade at G2M", ONCOGENE, (20050127), vol. 24, no. 5, ISSN 0950-9232, pages 829 - 837, XP002555750 [I] 1-8 * the whole document * [Y] 2 DOI: http://dx.doi.org/10.1038/sj.onc.1208227 | [IPY] - YAMOUTPOUR FARNAZ ET AL, "Gene silencing for epidermal growth factor receptor variant III induces cell-specific cytotoxicity", MOLECULAR CANCER THERAPEUTICS, (200811), vol. 7, no. 11, ISSN 1535-7163, pages 3586 - 3597, XP002555753 [IP] 1-8 * the whole document * [Y] 2 DOI: http://dx.doi.org/10.1158/1535-7163.MCT-08-0653 | [IY] - OUSSENKO IRINA ET AL, "SiRNAs against deletion mutant EGFR in the treatment of glioblastoma multiforme (GBM).", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, & 98TH ANNUAL MEETING OF THE AMERICAN-ASSOCIATION-FOR-CANCER-RESEARCH; LOS ANGELES, CA, USA; APRIL 14 -18, 2007, (200704), vol. 48, ISSN 0197-016X, page 1140, XP008114958 [I] 1-8 * the whole document * [Y] 2 | [IY] - ARWERT ESTHER ET AL, "Visualizing the dynamics of EGFR activity and antiglioma therapies in vivo", CANCER RESEARCH, (200708), vol. 67, no. 15, ISSN 0008-5472, pages 7335 - 7342, XP002555751 [I] 1-8 * the whole document * [Y] 2 DOI: http://dx.doi.org/10.1158/0008-5472.CAN-07-0077 | [IY] - T. L. LEE ET AL, "Epigenetic modification of SOCS-1 differentially regulates STAT3 activation in response to interleukin-6 receptor and epidermal growth factor receptor signaling through JAK and/or MEK in head and neck squamous cell carcinomas", MOLECULAR CANCER THERAPEUTICS, (20060101), vol. 5, no. 1, doi:10.1158/1535-7163.MCT-05-0069, ISSN 1535-7163, pages 8 - 19, XP055079299 [I] 1-8 * the whole document * [Y] 2 DOI: http://dx.doi.org/10.1158/1535-7163.MCT-05-0069 | [IPY] - COLOMIERE M ET AL, "Cross talk of signals between EGFR and IL-6R through JAK2/STAT3 mediate epithelial-mesenchymal transition in ovarian carcinomas", BRITISH JOURNAL OF CANCER, NATURE PUBLISHING GROUP, GB, (20081216), vol. 100, no. 1, ISSN 0007-0920, pages 134 - 144, XP009136953 [IP] 1-8 * the whole document * [Y] 2 | [IY] - SIZHI PAUL GAO ET AL, "Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas", JOURNAL OF CLINICAL INVESTIGATION, (20071203), vol. 117, no. 12, doi:10.1172/JCI31871, ISSN 0021-9738, pages 3846 - 3856, XP055109853 [I] 1-8 * the whole document * [Y] 2 DOI: http://dx.doi.org/10.1172/JCI31871 | [IY] - ZACHARY T. SCHAFER ET AL, "IL-6 involvement in epithelial cancers", JOURNAL OF CLINICAL INVESTIGATION, (20071203), vol. 117, no. 12, doi:10.1172/JCI34237, ISSN 0021-9738, pages 3660 - 3663, XP055109811 [I] 1-8 * the whole document * [Y] 2 DOI: http://dx.doi.org/10.1172/JCI34237 | [IPY] - SAIDI A ET AL, "Combined targeting of interleukin-6 and vascular endothelial growth factor potently inhibits glioma growth and invasiveness", INTERNATIONAL JOURNAL OF CANCER, JOHN WILEY & SONS, INC, US, vol. 125, no. 5, doi:10.1002/IJC.24380, ISSN 0020-7136, (20090223), pages 1054 - 1064, (20090223), XP002691431 [IP] 1-8 * the whole document * [Y] 2 DOI: http://dx.doi.org/10.1002/ijc.24380 | [A] - FAN Q-W ET AL, "COMBINATORIAL EFFICACY ACHIEVED THROUGH TWO-POINT BLOCKADE WITHIN A SIGNALING PATHWAY-A CHEMICAL GENETIC APPROACH", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, (20031215), vol. 63, no. 24, ISSN 0008-5472, pages 8930 - 8938, XP009056208 [A] 1-8 * the whole document * | [T] - M.-D.-M. INDA ET AL, "Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma", GENES & DEVELOPMENT, (20100815), vol. 24, no. 16, doi:10.1101/gad.1890510, ISSN 0890-9369, pages 1731 - 1745, XP055109929 [T] 1-8 * the whole document * DOI: http://dx.doi.org/10.1101/gad.1890510 | by applicant | US3687808 | US4426330 | US4469863 | US4476301 | US4534899 | US4587044 | US4605735 | US4667025 | WO8804924 | US4762779 | US4789737 | WO8902468 | US4824941 | US4828979 | US4835263 | US4837028 | WO8905345 | US4845205 | WO8907136 | US4868116 | US4876335 | US4904582 | WO9004384 | US4948882 | US4958013 | US4980286 | US4981957 | WO9105545 | US5013556 | US5023243 | US5032401 | US5034506 | US5082830 | US5109124 | US5112963 | WO9207573 | US5118800 | US5118802 | US5130302 | US5134066 | US5138045 | US5139941 | US5166315 | US5175273 | US5177195 | US5185444 | US5188897 | US5214134 | US5214136 | US5213804 | US5216141 | US5218105 | US5225212 | US5235033 | US5245022 | US5252479 | US5254469 | US5258506 | US5262536 | US5264423 | US5264562 | US5264564 | US5264221 | WO9324641 | US5272250 | US5276019 | US5278302 | US5286717 | US5292873 | EP0445131 | US5317098 | US5319080 | US5321131 | WO9413788 | US5328470 | WO9420073 | US5356633 | US5359044 | US5367066 | US5371241 | EP0496813 | US5391723 | US5393878 | US5399676 | US5405939 | US5405938 | US5414077 | US5416203 | US5432272 | US5434257 | US5446137 | US5451463 | US5453496 | US5455233 | US5457187 | US5459255 | US5466677 | US5466786 | US5470967 | US5476925 | US5484908 | US5486603 | US5489677 | US5502177 | WO9610391 | US5510475 | US5512439 | US5512667 | US5514785 | US5519126 | US5519134 | US5525711 | US5525465 | US5536821 | US5539082 | US5541316 | US5541307 | US5541313 | US5540935 | US5543152 | US5545730 | US5550111 | US5552540 | US5552538 | US5556948 | US5561225 | US5563253 | US5565552 | US5567811 | US5567810 | US5571799 | US5574142 | US5576427 | US5578717 | US5578718 | US5580731 | US5585481 | WO9640964 | WO9640062 | US5587361 | US5587469 | US5587371 | US5591722 | US5591584 | US5594121 | US5596086 | US5596091 | US5595726 | US5597909 | US5597696 | US5599923 | US5599928 | US5602240 | WO9704787 | US5607677 | US5608046 | US5610289 | US5610300 | US5614617 | US5618704 | WO9713499 | US5623070 | US5625050 | US5627053 | US5633360 | US5639873 | US5646265 | US5658873 | WO9730731 | US5663312 | US5665710 | US5670633 | US5677437 | US5677439 | US5681941 | US5688941 | US5700920 | US5705188 | US5714331 | US5719262 | US5750692 | US5814014 | WO9932619 | WO9953050 | US5976567 | US5981501 | WO9961631 | WO0003683 | WO0022113 | WO0022114 | US6054299 | US6093180 | WO0044895 | DE10100586 | US2003027780 | US6534484 | US6586410 | US6747014 | WO2004065601 | US6815432 | US6887906 | US2005281781 | US2006240093 | WO2007064846 | US2007135372 | WO2008042973 | US2008234218 | - YANG, D. ET AL., CURR. BIOL., (2000), vol. 10, pages 1191 - 1200 | - NISHIKAWA ET AL., "A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity", PROC. NATL. ACAD. SCI. USA, (1994), vol. 91, pages 7727 - 7731 | - NISHIKAWA ET AL., PNAS, (1994), vol. 91, pages 7727 - 7731 | - NAGANA ET AL., CANCER RESEARCH, (1996), vol. 56, pages 5079 - 5086 | - ELBASHIR, EMBO, (2001), vol. 20, pages 6877 - 6888 | - BEAUCAGE, S.L. ET AL., Current protocols in nucleic acid chemistry, JOHN WILEY & SONS, INC. | - NIELSEN ET AL., SCIENCE, (1991), vol. 254, pages 1497 - 1500 | - MARTIN ET AL., HELV. CHIM. ACTA, (1995), vol. 78, pages 486 - 504 | - KROSCHWITZ, J. L, The Concise Encyclopedia Of Polymer Science And Engineering, JOHN WILEY & SONS, (1990), pages 858 - 859 | - ENGLISCH ET AL., ANGEWANDTE CHEMIE, INTERNATIONAL EDITION, (1991), vol. 30, page 613 | - SANGHVI, Y S., "chapter 15", SANGHVI, Y S., CROOKE, S. T. AND LEBLEU, B, DsRNA Research and Applications, CRC PRESS, (1993), pages 289 - 302 | - SANGHVI, Y. S., CROOKE, S. T. AND LEBLEU, B., DsRNA Research and Applications, CRC PRESS, (1993), pages 276 - 278 | - LETSINGER ET AL., PROC. NATL. ACID. SCI. USA, (1989), vol. 86, pages 6553 - 6556 | - MANOHARAN ET AL., BIORG. MED. CHEM. LET., (1994), vol. 4, pages 1053 - 1060 | - MANOHARAN ET AL., ANN. N.Y. ACAD. SCI., (1992), vol. 660, pages 306 - 309 | - MANOHARAN ET AL., BIORG. MED. CHEM. LET., (1993), vol. 3, pages 2765 - 2770 | - OBERHAUSER ET AL., NUCL. ACIDS RES., (1992), vol. 20, pages 533 - 538 | - SAISON-BEHMOARAS ET AL., EMBO J, (1991), vol. 10, pages 1111 - 1118 | - KABANOV ET AL., FEBS LETT., (1990), vol. 259, pages 327 - 330 | - SVINARCHUK ET AL., BIOCHIMIE, (1993), vol. 75, pages 49 - 54 | - MANOHARAN ET AL., TETRAHEDRON LETT., (1995), vol. 36, pages 3651 - 3654 | - SHEA ET AL., NUCL. ACIDS RES., (1990), vol. 18, pages 3777 - 3783 | - MANOHARAN ET AL., NUCLEOSIDES & NUCLEOTIDES, (1995), vol. 14, pages 969 - 973 | - MISHRA ET AL., BIOCHIM. BIOPHYS. ACTA, (1995), vol. 1264, pages 229 - 237 | - CROOKE ET AL., J. PHARMACOL. EXP. THER., (1996), vol. 277, pages 923 - 937 | - LETSINGER ET AL., PROC. NATL. ACAD. SCI. USA, (1989), vol. 86, page 6553 | - MANOHARAN ET AL., BIOORG. MED. CHEM. LETT., (1994), vol. 4, page 1053 | - MANOHARAN ET AL., ANN. N.Y. ACAD. SCI., (1992), vol. 660, page 306 | - MANOHARAN ET AL., BIOORG. MED. CHEM. LET., (1993), vol. 3, page 2765 | - OBERHAUSER ET AL., NUCL. ACIDS RES., (1992), vol. 20, page 533 | - SAISON-BEHMOARAS ET AL., EMBO J., (1991), vol. 10, page 111 | - KABANOV ET AL., FEBS LETT., (1990), vol. 259, page 327 | - SVINARCHUK ET AL., BIOCHIMIE, (1993), vol. 75, page 49 | - MANOHARAN ET AL., TETRAHEDRON LETT., (1995), vol. 36, page 3651 | - SHEA ET AL., NUCL. ACIDS RES., (1990), vol. 18, page 3777 | - MANOHARAN ET AL., NUCLEOSIDES & NUCLEOTIDES, (1995), vol. 14, page 969 | - MISHRA ET AL., BIOCHIM. BIOPHYS. ACTA, (1995), vol. 1264, page 229 | - CROOKE ET AL., J. PHARMACOL. EXP. THER., (1996), vol. 277, page 923 | - COUTURE, A ET AL., TIG, (1996), vol. 12, pages 5 - 10 | - GASSMANN ET AL., PROC. NATL. ACAD. SCI. USA, (1995), vol. 92, page 1292 | - MUZYCZKA ET AL., CURRO TOPICS MICRO. IMMUNOL., (1992), vol. 158, pages 97 - 129 | - BERKNER ET AL., BIOTECHNIQUES, (1998), vol. 6, page 616 | - ROSENFELD ET AL., SCIENCE, (1991), vol. 252, pages 431 - 434 | - ROSENFELD ET AL., CELL, (1992), vol. 68, pages 143 - 155 | - EGLITIS ET AL., SCIENCE, (1985), vol. 230, pages 1395 - 1398 | - DANOS; MULLIGAN, PROC. NATI. ACAD. SCI. USA, (1998), vol. 85, pages 6460 - 6464 | - WILSON ET AL., PROC. NATI. ACAD. SCI. USA, (1988), vol. 85, pages 3014 - 3018 | - ARMENTANO ET AL., PROC. NATL. ACAD. SCI. USA, (1990), vol. 87, page 61416145 | - HUBER ET AL., PROC. NATL. ACAD. SCI. USA, (1991), vol. 88, pages 8039 - 8043 | - FERRY ET AL., PROC. NATL. ACAD. SCI. USA, (1991), vol. 88, pages 8377 - 8381 | - CHOWDHURY ET AL., SCIENCE, (1991), vol. 254, pages 1802 - 1805 | - VAN BEUSECHEM ET AL., PROC. NAD. ACAD. SCI. USA, (1992), vol. 89, pages 7640 - 19 | - KAY ET AL., HUMAN GENE THERAPY, (1992), vol. 3, pages 641 - 647 | - DAI ET AL., PROC. NATLACAD. SCI. USA, (1992), vol. 89, pages 10892 - 10895 | - HWU ET AL., J. IMMUNOL., (1993), vol. 150, pages 4104 - 4115 | - COMETTE ET AL., HUMAN GENE THERAPY, (1991), vol. 2, pages 5 - 10 | - CONE ET AL., PROC. NATL. ACAD. SCI. USA, (1984), vol. 81, page 6349 | - HSU, J. INFECTIOUS DISEASE, (1992), vol. 166, page 769 | - RABINOWITZ J E ET AL., J VIROL, (2002), vol. 76, pages 791 - 801 | - DOMBURG.R, GENE THERAP., (1995), vol. 2, pages 301 - 310 | - EGLITIS M A, BIOTECHNIQUES, (1988), vol. 6, pages 608 - 614 | - MILLER A D, HUM GENE THERAP., (1990), vol. 1, pages 5 - 14 | - ANDERSON W F, NATURE, (1998), vol. 392, pages 25 - 30 | - RUBINSON D A ET AL., NAT. GENET., vol. 33, pages 401 - 406 | - XIA H ET AL., NAT. BIOTECH., (2002), vol. 20, pages 1006 - 1010 | - SAMULSKI R ET AL., J. VIROL., (1987), vol. 61, pages 3096 - 3101 | - FISHER K J ET AL., J. VIROL, (1996), vol. 70, pages 520 - 532 | - SAMULSKI R ET AL., J. VIROL., (1989), vol. 63, pages 3822 - 3826 | - BUCCHINI ET AL., PROC. NATL. ACAD. SCI. USA, (1986), vol. 83, pages 2511 - 2515 | - DOCHERTY ET AL., FASEB J, (1994), vol. 8, pages 20 - 24 | - CHEN ET AL., PROC. NATL. ACAD. SCI., (1994), vol. 91, pages 3054 - 3057 | - IDSON, IDSON, LIEBERMAN, RIEGER AND BANKER, Pharmaceutical Dosage Forms, MARCEL DEKKER, INC., (1988), vol. 1, page 199 | - ROSOFF, ROSOFF, LIEBERMAN, RIEGER AND BANKER, Pharmaceutical Dosage Forms, MARCEL DEKKER, INC., (1988), vol. 1, page 245 | - BLOCK, BLOCK, LIEBERMAN, RIEGER AND BANKER, Pharmaceutical Dosage Forms, MARCEL DEKKER, INC, (1988), vol. 2, page 335 | - HIGUCHI ET AL., Remington's Pharmaceutical Sciences, MACK PUBLISHING CO., (1985), page 301 | - RIEGER, RIEGER, LIEBERMAN, RIEGER AND BANKER, Pharmaceutical Dosage Forms, Lieberman, MARCEL DEKKER, INC., (1988), vol. 1, page 285 | - LEUNG; SHAH, LEUNG; SHAH, ROSOFF, M., Controlled Release of Drugs: Polymers and Aggregate Systems, VCH PUBLISHERS, (1989), pages 185 - 215 | - SCHOTT, Remington's Pharmaceutical Sciences, MACK PUBLISHING CO., (1985), page 271 | - CONSTANTINIDES ET AL., PHARMACEUTICAL RESEARCH, (1994), vol. 11, pages 1385 - 1390 | - RITSCHEL, METH. FIND. EXP. CLIN. PHARMACOL., (1993), vol. 13, page 205 | - CONSTANTINIDES, PHARMACEUTICAL RESEARCH, (1994), vol. 11, page 1385 | - HO ET AL., J. PHARM. SCI., (1996), vol. 85, pages 138 - 143 | - LEE ET AL., CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS, (1991), page 92 | - WANG ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., (1987), vol. 147, pages 980 - 985 | - ZHOU ET AL., JOURNAL OF CONTROLLED RELEASE, (1992), vol. 19, pages 269 - 274 | - WEINER ET AL., JOURNAL OF DRUG TARGETING, (1992), vol. 2, pages 405 - 410 | - DU PLESSIS ET AL., ANTIVIRAL RESEARCH, (1992), vol. 18, pages 259 - 265 | - HU ET AL., S.T.P.PHARMA. SCI., (1994), vol. 4, no. 6, page 466 | - ALLEN ET AL., FEBS LETTERS, (1987), vol. 223, page 42 | - WU ET AL., CANCER RESEARCH, (1993), vol. 53, page 3765 | - PAPAHADJOPOULOS ET AL., ANN. N.Y. ACAD. SCI., (1987), vol. 507, page 64 | - GABIZON ET AL., PROC. NATL. ACAD. SCI. U.S.A., (1988), vol. 85, page 6949 | - SUNAMOTO ET AL., BULL. CHEM. SOC. JPN., (1980), vol. 53, page 2778 | - ILLUM ET AL., FEBS LETT., (1984), vol. 167, page 79 | - KLIBANOV ET AL., FEBS LETT., (1990), vol. 268, page 235 | - BLUME ET AL., BIOCHIMICA ET BIOPHYSICA ACTA, (1990), vol. 1029, page 91 | - LEE, CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS, (1991), page 92 | - TAKAHASHI ET AL., J. PHARM. PHANNACOL., (1988), vol. 40, page 252 | - LEE ET AL., CRITICAL REVIEWS IN THERAPEUTIC DRUG CANYIER SYSTEMS, (1991), page 92 | - MURANISHI, CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS, (1990), vol. 7, pages 1 - 33 | - EL HARIRI ET AL., J. PHARM. PHARMACOL., (1992), vol. 44, pages 651 - 654 | - BRUNTON, "Chapter 38", BRUNTON, HARDMAN ET AL., Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th ed., MCGRAW-HILL, (1996), pages 934 - 935 | - SWINYARD, "Chapter 39", SWINYARD, GENNARO, Remington's Pharmaceutical Sciences, 18th ed., MACK PUBLISHING CO., (1990), pages 782 - 783 | - YAMAMOTO ET AL., J. PHARM. EXP. THER., (1992), vol. 263, page 25 | - YAMASHITA ET AL., J. PHARM. SCI., (1990), vol. 79, pages 579 - 583 | - JARRETT, J. CHROMATOGR., (1993), vol. 618, pages 315 - 339 | - BUUR ET AL., J. CONTROL REL., (1990), vol. 14, pages 43 - 51 | - YAMASHITA ET AL., J. PHARM. PHARMACOL., (1987), vol. 39, pages 621 - 626 | - MIYAO ET AL., DSRNA RES. DEV., (1995), vol. 5, pages 115 - 121 | - TAKAKURA ET AL., DSRNA & NUCL. ACID DRUG DEV., (1996), vol. 6, pages 177 - 183 | - BERKOW ET AL., The Merck Manual of Diagnosis and Therapy, 15th ed., (1987), pages 1206 - 1228 | - BERKOW ET AL., The Merck Manual of Diagnosis and Therapy, 15th ed., (1987), pages 2499 - 2506,46- | - BEAUCAGE, S.L. ET AL., Current protocols in nucleic acid chemistry, JOHN WILEY & SONS, INC | - LAL S. ET AL., JNEUROSURG, (2000), vol. 92, no. 2, pages 326 - 333 | - BACHOO ET AL., CANCER CELL, (2002), vol. 1, pages 269 - 77 | - NAGANE ET AL., CANCER RESEARCH, (1996), vol. 56, pages 5079 - 5086 | US20080045228 |